Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Sees Strong Trading Volume – Here’s What Happened

Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF) shares saw unusually-high trading volume on Friday . Approximately 200 shares were traded during mid-day trading, an increase of 9% from the previous session’s volume of 184 shares.The stock last traded at $58.75 and had previously closed at $56.95.

Analysts Set New Price Targets

Several research analysts recently commented on RCDTF shares. Barclays upgraded shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets upgraded shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Trading Up 5.1%

The stock has a market cap of $12.12 billion, a price-to-earnings ratio of 22.23 and a beta of 0.23. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 1.13. The business’s 50 day simple moving average is $56.62 and its 200 day simple moving average is $61.70.

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.08 EPS for the quarter. The firm had revenue of $834.86 million during the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 35.19%.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.